Barbara J. Fisher, MD, FRCPC

Radiation Oncologist, Verspeeten Family Cancer Centre

Professor, Schulich School of Medicine & Dentistry, University of Western Ontario

Current Practice

  • Department of Radiation Oncology, Verspeeten Family Cancer Centre, London Health Science Centre
  • Professor, Department of Oncology, UWO, Senate Stream
  • Clinician Scientist, Ontario Associate Radiation Oncologists

Areas of Interest

  • Radiation Oncology, Central Nervous System (CNS), Skin,  Gastrointestinal (GI) tumours, Photodynamic treatment, Clinical Research

Education

  • University of Western Ontario Medical School, London, Ontario - Doctor of Medicine

Postgraduate Education

  • Internship - Victoria Hospital, London, Ontario
  • Resident - Department of Radiation Oncology, University of Ottawa, Princess Margaret Hospital, Ottawa, Ontario
  • Fellow - Department of Radiation Oncology, Ottawa Regional Cancer Centre, Ottawa, Ontario
  • Postdoctoral Fellow - Stanford University, Palo Alto, California
Grants

Non-Industry

2016-2018: Principal Investigator, AMOSO Grant: Translating the Clinical Utility of Circulating Cancer Microparticle Enumeration for Determining Prognosis of Colorectal Cancer Funded: $166,250

2013-2015: Co-Investigator OICR-HICT grant:  Microparticle Analysis Pancreatic Cancer Funded $101,806 PI:  Ann Chambers

2013-2015: Principal Investigator, OICR-HICT Grant: Translating the Clinical Utility of Cancer Microparticle Enumeration and Functional Tumor Imaging for Combined Prognosis of Colorectal Cancer.  Funded $58,840

2012-2014: Coapplicant Verspeeten Family Cancer Centre Catalyst Grant:  Microparticle Analysis in Colorectal Cancer Patients with Hepatic Metastases Receiving Stereo-ablative Radiotherapy, Funded $29,637.50  PI:  Michael Lock

2012-2014: Coapplicant CFI Grant: A large Area Detector Dual Energy CT Scanner for Low Radiation Dose Functional Imaging Research in Oncology and Cardiology. Funded $961,524  PI: Ting Lee

2011-2014: Principal Investigator, CASARIA Grant: Prospective Study of PET-CT and 3T MRI in Assessing Tumor Response after Neoadjuvant Chemoradiation for Rectal Cancer, Canadian Radiation Oncology Foundation, Funded $22,281

2011-2016: Collaborator, CASARIA Grant: Circulating Tumor Cell Analysis in Colorectal Patients with Hepatic Oligometastases, Canadian Radiation Oncology Foundation, Funded $24,960, PI: Michael Lock

2011: Principal Investigator, CASARIA Grant: Rectal Cancer: Local Staging, Re-Staging and Assessment of Lymph Node Metastases Using 3T MRI-PET and CT Perfusion, CASARIA (Canadian Radiation Oncology Foundation/ Sanofi-Aventis) Award, Funded $22,281 and $15,000.00 from Surgical Oncology Fund, London Health Sciences Hospital

Publications
  • Buckner J, Shaw E, Pugh S, Chakravarti A, Gilbert M, Barger G, Coons S, Ricci P, Bullard D, Brown P,  Stelzer K, Brachman D, Suh J, Schultz C, Bahary JP, Fisher B, Kim H, Murtha A, Bell E, Won M, Mehta M, Curran W Jr.  Radiation Plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma.  New England Journal of Medicine, Accepted in Press
  • Fisher B, Hu C, Macdonald D, Lesser L , Coons S, Brachman D, Ryu S, Werner-Wasik M, Bahary J, Liu J , Chakravarti A, Mehta M.  Phase II study of a temozolomide-based Chemo-radiotherapy Regimen for high risk low-grade gliomas:  Preliminary results of Radiation Therapy Oncology Group (RTOG) 0424. Int J Radiat Oncol Biol Phys 2015 Mar 1;91(3):497-504.
  • Panageas K, Reiner A, Iwamoto F, Cloughesy T, Aldape K, Rivera A, Eichler A, Louis D, Paleologos N, Fisher B et al. Recursive partitioninganalysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors. Neuro Oncol. 2014 Nov;16(11):1541-6.
  • Boychak A, Bauman G, Fisher B, Abdulkarim BAmanie JFulton DMurtha APatel SUrtasun RGhosh SRoa WH. A Phase I Study of Tomotherapy in Patients with Primary Benign and Low-Grade Bran Tumors: Late Toxicity and Quality of Life.  Am J Clin Oncol 2014 Jan epub
  • Jensen NK, Mulder D, Lock M, Fisher B, Zener R, Beech B, Kozak R, Chen J, Lee TY, Wong E.  Dynamic contrast enhanced CT aiding gross tumor volume delineation of liver tumors: An interobserver variability study.  Radiother Oncol. 2014 Apr;111(1):153-7.
  • Yeung TPC, Yartsev, Lee TY, Wong E, He W, Fisher B, VanderSpek L, Macdonald D, Bauman G. Relationship of computed tomography perfusion and positron emission tomography to tumour progression in malignant glioma. Med Radiat Sci. 2014 Feb;61(1):4-13. 
  • Jensen NK, Stewart E, Lock M, Fisher B, Kozak R, Chen J, Lee TY, Wong E. Assessment of contrast enhanced respiration managed cone-beam CT for image guided radiotherapy of intrahepatic tumors. Med Phys. 2014 May;41(5):051905.
  • Jensen N, Lock M, Fisher B, Kozak R, Chen X, Chen J, Wong E, Lee T.  Prediction and reduction of motion artifacts in free-breathing dynamic contrast enhanced CT perfusion imaging of primary and metastatic intrahepatic tumours. Acad Radiol. 2013 Apr;20(4):414-22.
  • Louie A, Chan E, Hanna M, Bauman G, Fisher B, Palma D Rodrigues G, Warner A, D’Souza D. Fitness to drive in brain tumour patients:  A Gray Matter of Law, Ethics, and Medicine. Curr Oncol. 2013 Apr; 20(2): 90–96.
  • Chan E, Louie A, Hanna M, Bauman G, Fisher B, Palma D, Rodrigues G, Sathya A , D’Souza D.   Multidisciplinary Assessment of Fitness to Drive in Brain Tumour Patients in Southwestern Ontario: A Grey Matter. Curr Oncol. 2013 Feb; 20(1): e4–e12.
  • Chia J, Louie A, Jordan K, Gilchrist J, Fisher B, D’Souza D.  Topical PDT for the Treatment of Carcinoma in Situ of the Penis. Cureus 2013: December
  • Louie A, D’Souza D, Palma D, Bauman G, Lock M, Fisher B, Patil N, Rodrigues G. Fitness to drive in patients with brain tumors: The influence of mandatory reporting legislation on radiation oncologists in Canada. Curr Oncol. 2012 Jun;19(3):e117-2.
  • Panageas KS, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Cairncross JG, Roldán Urgoiti GB, Wen PY, Ligon KL, Schiff D, Robins HI, Rocque BG, Chamberlain MC, Mason WP, Weaver SA, Green RM, Kamar FG, Abrey LE, Deangelis LM, Jhanwar SC, Rosenblum MK, Lassman AB.  Initial Treatment Patterns over Time for Anaplastic Oligodendroglial Tumors. Neuro Oncol. 2012 Jun;14(6):761-7.
  • Cao J, Fisher B, Bauman G, Macdonald D, Megyesi J, Watling C. Hypofractionated Radiation plus Concurrent and Adjuvant versus Salvage Temozolomide in Elderly Patients with Glioblastoma. J Neurooncol. 2012 Apr;107(2):395-405. 
  • Lassman A, Fabio M, Iwamoto T, Coughnesy F, Aldape K, Rivera A, Eichler A, Louis D, Paleologos A, Fisher B, Ashby L, Cairncross JG, Roldan G, Wen P, Ligon K, Schiff D, Robins I, Rocque B, Chamberlain M, Mason W, Weaver S, Green R, Kamar F, Abrey L, DeAngelis L, Jhanwar S, Rosenblum M, Panageas K. International retrospective study of over 1000 adults with anaplastic oligodendrogioma tumours  Neuro Oncol. 2011 Jun;13(6):649-59.
  • Hallock A, Hamilton B, Ang C, Tay K, Megyesi J, Fisher B, Watling C, Macdonald D, Bauman G.  Neurocytoma: Long-term Experience at a Single Institution. Neuro Oncol. 2011 Sep;13(9):943-9.
  • Yoon F, Perera F, Fisher B, Stitt L. Alterations in hormone levels after adjuvant chemoradiation in male rectal cancer patients. Int J Radiat Oncol Biol Phys 74(4);1186-90, 2009.
  • Bauman G, Fisher B, Watling C, Cairncross JG, Macdonald D. Adult supratentorial low-grade glioma:  long-term experience at a single institution. Int J Radiat Oncol Biol Phys 75(5):1401-7, 2009.